Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lenhoff

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Blood|May 1, 1994
A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation GroupO Ringdén, T Ruutu, M Remberger, et al.
Transplantation Proceedings|June 1, 1994
A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignanciesO Ringdén, T Ruutu, M Remberger, et al.
Blood|March 26, 1999
Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation GroupO Ringdén, M Remberger, T Ruutu, et al.
Bone Marrow Transplantation|February 1, 1997
No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT GroupT Ruutu, P Ljungman, L Brinch, et al.
Bone Marrow Transplantation|May 10, 2011
The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countriesJ Abelsson, M Merup, G Birgegård, et al.
Bone Marrow Transplantation|June 30, 2015
Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trialP Gimsing, Ø Hjertner, N Abildgaard, et al.
Leukemia|February 1, 2012
Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMTA Spyridonidis, M Labopin, C Schmid, et al.
Medical Oncology (Northwood, London, England)|January 10, 2002
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell supportN Gulbrandsen, F Wisløff, L Brinch, et al.
Bone Marrow Transplantation|July 28, 2009
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMTY Chalandon, J R Passweg, C Schmid, et al.
British Journal of Haematology|March 23, 1999
Linear reduction of clonal cells in stem cell enriched grafts in transplanted multiple myelomaU Thunberg, M Bånghagen, M Bengtsson, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Blood|May 1, 1994
A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation GroupO Ringdén, T Ruutu, M Remberger, et al.
Transplantation Proceedings|June 1, 1994
A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignanciesO Ringdén, T Ruutu, M Remberger, et al.
Blood|March 26, 1999
Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation GroupO Ringdén, M Remberger, T Ruutu, et al.
Bone Marrow Transplantation|February 1, 1997
No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT GroupT Ruutu, P Ljungman, L Brinch, et al.
Bone Marrow Transplantation|May 10, 2011
The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countriesJ Abelsson, M Merup, G Birgegård, et al.
Bone Marrow Transplantation|June 30, 2015
Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trialP Gimsing, Ø Hjertner, N Abildgaard, et al.
Leukemia|February 1, 2012
Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMTA Spyridonidis, M Labopin, C Schmid, et al.
Medical Oncology (Northwood, London, England)|January 10, 2002
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell supportN Gulbrandsen, F Wisløff, L Brinch, et al.
Bone Marrow Transplantation|July 28, 2009
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMTY Chalandon, J R Passweg, C Schmid, et al.
British Journal of Haematology|March 23, 1999
Linear reduction of clonal cells in stem cell enriched grafts in transplanted multiple myelomaU Thunberg, M Bånghagen, M Bengtsson, et al.
Pageof 4